The authors framed their report as a guidebook to help regulatory agencies across the globe coordinate "consistent" rules while allowing for societal differences.
IDT has licensed the CRISPR/Cpf1 RNA-guided editing system from the Broad Institute and intends to sell it to pharmaceutical and other commercial labs.
The firms will continue to develop strains of algae that demonstrate improved photosynthetic efficiency and oil production.
Researchers uncover anti-CRISPR proteins that could help genetic engineering to be safer.
In PNAS this week: deep phenotyping of xeroderma pigmentosum, role of PREX2 mutations in melanoma development, and more.
Wired writes that CRISPR could change the world — in many imaginative ways — and whether it will be for the better is still in the air.
The recent funding round follows $25 million that the company raised in January 2010.
In Brief This Week is a Friday column containing news items that our readers may have missed during the week.
The drug maker Daiichi Sankyo will use Gene Bridges' DNA recombination technology.
University of Illinois at Urbana-Champgain, 23andMe, Michael J. Fox Foundaton for Parkinson's Research, Parkinson's Institute and Clinical Center, SeqWright, Roche NimbleGen, Chronix Biomedical, Genome Atlantic, Agilent Technologies
Dog DNA testing finds that some purebreds might not truly be purebreds, Inside Edition reports.
Mary Beckerle has returned as director of the Huntsman Cancer Institute, according to ScienceInsider.
Smithsonian Magazine reports that environmental DNA sampling can be used to track elusive organisms.
In Genome Research this week: repetitive satellite DNA in the fruit fly, transcriptome map assembly pipeline, and more.